Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany.
Clin Chem Lab Med. 2011 May;49(5):855-60. doi: 10.1515/CCLM.2011.132. Epub 2011 Feb 3.
The Luminescent Oxygen Channeling Immunoassay (LOCI) technology is a well-established homogeneous assay format that allows for fast, accurate, and highly sensitive quantitation of analytes. We set out to develop and prove a novel concept to establish a LOCI format that should principally allow for the determination of the activity of coagulation factors and anticoagulants of clinical relevance.
The concept is based on the linkage of LOCI nano-beads by a peptide that can be cleaved by a coagulation factor. To prove the principle, we used a peptide that can be cleaved by thrombin.
We were able to show that coagulation activation of plasma or whole blood samples that were combined with the LOCI components degraded the thrombin-sensitive peptide and consequently, led to a reduction of the LOCI signal. Signal reduction was proportional to the amount of active thrombin generated. The research prototype assay allowed for the detection of factor deficiencies in both the extrinsic and intrinsic coagulation pathways, and for the quantification of hirudin, a direct thrombin inhibitor.
Taken together, we conclude that the LOCI technology has the potential for extension to functional blood coagulation assays.
发光氧通道免疫测定（LOCI）技术是一种成熟的均相测定方法，可快速、准确、高度灵敏地定量分析物。我们着手开发并证明了一个新概念，以建立一种 LOCI 格式，主要用于确定具有临床相关性的凝血因子和抗凝剂的活性。
该概念基于通过肽连接 LOCI 纳米珠，该肽可被凝血因子切割。为了证明原理，我们使用了一种可被凝血酶切割的肽。
我们能够表明，与 LOCI 成分结合的血浆或全血样本的凝血激活会降解凝血酶敏感肽，从而导致 LOCI 信号减少。信号减少与生成的活性凝血酶的量成正比。研究原型测定法可检测外源性和内源性凝血途径中的因子缺乏，并可定量检测直接凝血酶抑制剂水蛭素。
总的来说，我们得出结论，LOCI 技术有可能扩展到功能性血液凝血测定。
